Findings

What do systematic reviews say?

65 questions · 66 findings · 17 reviews · Neuromuscular

No studies found 6 · 9.1%GRADE not reported 19 · 28.8%Very low 19 · 28.8%Low 6 · 9.1%Moderate 9 · 13.6%High 7 · 10.6%

Rate of decline in MVIC Expressed as arm megascore1 · people with ALS/MND

1 finding from 1 review

Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 345 participants
High

Rate of decline of % predicted FVC · people with ALS/MND

1 finding from 1 review

Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 274 participants
High

Rate of decline (per month) of functional rating scale (over a period of 9 months) Measured by ALSFRS‐R · people with ALS/MND

1 finding from 1 review

Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 128 participants
Moderate

Health‐related quality of life Short Form 12 Health Survey (SF‐12) · people with ALS/MND

1 finding from 1 review

Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 128 participants
Moderate

Adverse events · people with ALS/MND

1 finding from 1 review

Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 353 participants
High